Outpatient Treatment of Postbariatric Hypoglycemia With Canagliflozin
Abstract
Background/Objective The goal of this study was to examine canagliflozin’s efficacy in treating postbariatric hypoglycemia (PBH) in a real-world setting. We hypothesized that canagliflozin, a sodium-glucose cotransporter 1/2 inhibitor, would reduce postprandial hyperglycemia and hypoglycemia. Case Report Retrospective analysis was performed on continuous glucose monitor data of 4 patients (3 females and 1 male) with PBH from Roux-en-Y gastric bypass who took canagliflozin 300 mg daily. The number of postprandial hyperglycemic (180-250 mg/dL and >250 mg/dL) and hypoglycemic (54-69 mg/dL and <54 mg/dL) episodes in a 4-week period before canagliflozin was started and a 4-week period on canagliflozin was compared using paired t-test statistics. Patients’ subjective reports of PBH symptoms prior to and on canagliflozin were obtained from review of chart notes. Discussion Although canagliflozin was well tolerated with 1 reported urinary tract infection, canagliflozin did not significantly reduce hypoglycemic episodes or attenuate postprandial hyperglycemic excursions depicted on continuous glucose monitor. Subjectively, most patients did not report improvement in PBH symptoms. This led to discontinuation of canagliflozin in 3 of the 4 cases. Conclusion Canagliflozin was not found to reduce postprandial hyperglycemia or hypoglycemia in PBH. Because sodium-glucose cotransporter 1 inhibition is brief and transient, it is likely that the postulated beneficial effects of canagliflozin…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Antioxidant efficacy and the upregulation of Nrf2-mediated HO-1 expression by (+)-lariciresinol, a lignan isolated from Rubia philippinensis, through the activation of p38
- Anti-influenza virus activity of green tea by-products in vitro and efficacy against influenza virus infection in chickens
- Therapeutic Potential of Mesenchymal Stem Cells (MSCs) and MSC-Derived Extracellular Vesicles for the Treatment of Spinal Cord Injury
- The intratumoral administration of ferucarbotran conjugated with doxorubicin improved therapeutic effect by magnetic hyperthermia combined with pharmacotherapy in a hepatocellular carcinoma model
- Enhanced anticancer efficacy of TRAIL-conjugated and odanacatib-loaded PLGA nanoparticles in TRAIL resistant cancer
- In vivo tracking of bioorthogonally labeled T-cells for predicting therapeutic efficacy of adoptive T-cell therapy
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.